We are driven by a singular mission: Apply known biology to create novel, easy to administer therapies that materially benefit patients with autoimmune diseases. Our team is led by industry experts with a track record of stakeholder value creation.
Our Approach
We are pioneering a new frontier in autoimmune therapy with T-cell engager antibodies. By precisely redirecting T-cells to selectively eliminate autoreactive B-cells, we aim to achieve transformative efficacy safely. Our approach is grounded in rigorous scientific research and a deep understanding of immunological mechanisms.
Potential value of T-Cell Engagers
Approved B-cell therapies such as Rituxan® have demonstrated significant clinical benefit in a broad range of autoimmune diseases but efficacy is potentially limited by depth of B-cell depletion. Cell therapy approaches have demonstrated initial compelling proof of concept efficacy on the benefits of deeper depletion of B-cells; however, the burdensome process of a cell therapy approach, involving lymphodepletion and high cost of manufacturing is likely to limit cell therapy’s usage to only a selected set of patients.
T-cell engagers have the potential to overcome traditional hurdles of antibody and cellular therapy approaches and become highly effective and viable therapies for various autoimmune diseases. By additionally engaging T-cells, a deeper depletion of B-cells and more durable therapeutic could be realized. T-cell engagers have the potential to change the treatment paradigm in various autoimmune diseases and establish a new standard of care.